Participant demographics
| Variable* | Depression n = 12 | Control n = 23 | Significant difference between groups |
|---|---|---|---|
| Sex, n | 8 female, 4 male | 11 female, 12 male | No |
| Age, yr | 54.9 ± 4.5 | 60.3 ± 8.5 | No |
| Level of education, yr | 17.1 ± 4.0 | NA | NA |
| TSPO status, n | 8 HAB, 4 MAB | 12 HAB, 11 MAB | No |
| Injected dose [18F]FEPPA, MBq | 222.7 ± 50.0 | 204.6 ± 49.9 | No |
| Montreal Cognitive Assessment score† | 26.5 ± 2.1 | NA | NA |
| HAM-D score | 18.9 ± 7.1 | NA | NA |
| Suicidality, % | 66.7 | NA | NA |
| Psychosis, % | 8.3 | NA | NA |
| Age of onset, yr‡ | 30.4 ± 13.8 | NA | NA |
[18F]FEPPA = [18F]N-2-(fluoroethoxl)benzyl-N-(4phenoxypyridin-3-yl) acetamide; HAB = high-affinity binder; HAM-D = 17-item Hamilton Depression Rating Scale; MAB = mixed-affinity binder; NA = not applicable; TSPO = translocator protein.
↵* All means include ± standard deviation.
↵† Missing data from 1 participant.
↵‡ Missing data from 2 participants.